Research onlyGrowth hormoneSubcutaneousEvidence 2/5

IGF-1 LR3

Also known as: Long R3 IGF-1

A modified IGF-1 that binds IGF binding proteins far more weakly than native IGF-1, leaving it free to act as a potent, long-acting agonist at the IGF-1 receptor.

IGF-1 LR3
Drug class
IGF-1 analog / IGF-1 receptor agonist (research reagent)
Primary targets
IGF-1R
Dose reference
No validated human dose; research reagent only
Half-life
~20-30 hours (reported, non-clinical estimate)
Developer / origin
GroPep Ltd (Adelaide, Australia)
Reference year
1992
Evidence score
2/5 - Preclinical / reagent only
Evidence 2/5

Preclinical / reagent only

IGF-1 LR3 is well characterized as a cell-culture supplement and in animal infusion studies, but there is essentially no controlled human therapeutic data.

Mostly animal, ex vivo, cell, or indirect evidence.

Evidence basis

  • Reduced IGFBP affinity with retained IGF-1R binding
  • Validated potency in serum-free cell culture
  • Animal infusion studies showing disproportionate organ growth
  • No published controlled human therapeutic trials

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

IGF-1 LR3 guides

Read the matching guide or adjacent research pages for more context.

Peptide calculators

Use calculators for concentration, unit conversion and repeated-dose accumulation math.

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Ipamorelin

NNC 26-0161

3/5
Growth hormoneResearch only

Selectively stimulates pituitary growth hormone release without significant cortisol or prolactin elevation seen with older GHRPs.

CJC-1295

DAC:GRF

3/5
Growth hormoneResearch only

Long-acting growth-hormone-releasing hormone analog. The DAC variant binds serum albumin to extend half-life and sustain GH/IGF-1 elevation.

5/5
Growth hormoneApproved

Stabilized GHRH analog. Approved for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy.

IGF-1 DES

DES(1-3) IGF-1

2/5
Growth hormoneResearch only

Removal of the N-terminal tripeptide sharply lowers IGF-binding-protein affinity while preserving IGF-1 receptor binding, leaving more free peptide to activate IGF-1R.

Category hub

Open the category page for the full comparison table and FAQ.

Research & educational purposes only

The information on PeptideStat is for educational and research purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use. Always consult a qualified healthcare professional before making any health decisions. Articles may contain affiliate links — we may earn a commission at no extra cost to you.